Ask a doctor about a prescription for RIVASTIGMINE SANDOZ 1.5 mg HARD CAPSULES
Package Leaflet: Information for the Patient
Rivastigmine Sandoz 1.5mg hard capsules EFG
Rivastigmine Sandoz 3mg hard capsules EFG
Rivastigmine Sandoz 4.5mg hard capsules EFG
Rivastigmine Sandoz 6mg hard capsules EFG
rivastigmine
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the package leaflet:
The active substance of Rivastigmine Sandoz is rivastigmine.
Rivastigmine belongs to a group of substances called cholinesterase inhibitors. In patients with Alzheimer's dementia or dementia due to Parkinson's disease, certain nerve cells in the brain die, causing a reduction in the levels of the neurotransmitter acetylcholine (a substance that allows communication between nerve cells). Rivastigmine blocks the enzymes that destroy acetylcholine: acetylcholinesterase and butyrylcholinesterase. By blocking these enzymes, Rivastigmine Sandoz allows the levels of acetylcholine in the brain to increase, helping to reduce the symptoms of Alzheimer's disease and dementia associated with Parkinson's disease.
Rivastigmine Sandoz is used to treat adult patients with mild to moderately severe Alzheimer's disease, a progressive brain disorder that gradually affects memory, intellectual ability, and behavior. The capsules and oral solution can also be used to treat dementia in adult patients with Parkinson's disease.
Do not take Rivastigmine Sandoz
If you are in one of these situations, inform your doctor and do not take Rivastigmine Sandoz.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Rivastigmine Sandoz.
If you are in one of these situations, your doctor may consider it necessary to monitor you more closely while you are being treated.
If you have not taken Rivastigmine Sandoz for more than three days, do not take the next dose until you have spoken to your doctor.
Rivastigmine Sandoz is not recommended for use in children or adolescents (under 18 years of age).
Children and adolescents
There is no specific recommendation for the use of Rivastigmine Sandoz in the pediatric population for the treatment of Alzheimer's dementia.
Use of other medications and Rivastigmine Sandoz
Inform your doctor or pharmacist if you are using, have recently used, or may need to use any other medication.
Rivastigmine Sandoz should not be administered at the same time as other medications with similar effects to those of Rivastigmine Sandoz. Rivastigmine Sandoz may interfere with anticholinergic medications (medications used to relieve stomach cramps or spasms, for the treatment of Parkinson's disease, or to prevent travel sickness).
Rivastigmine Sandoz should not be administered with metoclopramide (a medication used to relieve or prevent nausea and vomiting). Taking the two medications at the same time could cause problems such as stiffness of the limbs and hand tremors.
If you need to undergo surgery while taking Rivastigmine Sandoz, inform your doctor before you are given any anesthetic, as Rivastigmine Sandoz may exaggerate the effects of some muscle relaxants during anesthesia.
Be cautious when taking Rivastigmine Sandoz with beta-blockers (medications, such as atenolol, used to treat high blood pressure, angina, and other heart conditions). Taking the two medications at the same time could cause problems such as a decrease in heart rate (bradycardia), leading to fainting or loss of consciousness.
Be cautious when taking Rivastigmine Sandoz with other medications that may affect heart rate or the heart's electrical system (prolongation of the QT interval).
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
If you are pregnant, the benefits of using Rivastigmine Sandoz should be evaluated against the potential effects on the fetus. Rivastigmine Sandoz should not be used during pregnancy, unless clearly necessary.
You should not breastfeed while taking Rivastigmine Sandoz.
Driving and using machines
Your doctor will indicate whether your condition allows you to drive or use machinery safely. Rivastigmine Sandoz may cause dizziness and drowsiness, mainly at the start of treatment or when the dose is increased. If you feel dizzy or drowsy, do not drive or use machinery, and do not perform other tasks that require your attention.
Follow the administration instructions of this medication exactly as indicated by your doctor. If you are in doubt, consult your doctor or pharmacist again.
How to start treatment:
Your doctor will indicate what dose of Rivastigmine Sandoz you should take.
Your doctor will regularly check if the medication is working for you. Your doctor will also check your weight while you are taking this medication.
If you have not taken Rivastigmine Sandoz for more than three days, do not take the next dose until you have consulted your doctor.
Taking this medication:
If you take more Rivastigmine Sandoz than you should
If you accidentally take more Rivastigmine Sandoz than you should, inform your doctor. You may need medical attention. Some people who have taken accidentally higher doses have experienced nausea, vomiting, diarrhea, high blood pressure, and hallucinations. There may also be a slowing of the heart rate and fainting.
If you forget to take Rivastigmine Sandoz
If you forget your dose of Rivastigmine Sandoz, wait and take the next dose at the usual time. Do not take a double dose to make up for the forgotten doses.
If you have any doubts about the use of this medication, consult your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not all people experience them.
You may experience side effects more frequently when you start taking your medication or when your dose is increased. Generally, side effects will disappear slowly as your body gets used to the medication.
Very common(may affect more than 1 in 10 patients)
Common(may affect up to 1 in 10 patients)
Uncommon(may affect up to 1 in 100 patients)
Rare(may affect up to 1 in 1,000 patients)
Very rare(may affect up to 1 in 10,000 patients)
Not known(frequency cannot be estimated from the available data)
Patients with dementia or Parkinson's disease
These patients experience some side effects more frequently and also have some additional side effects:
Very common(may affect more than 1 in 10 patients)
Common(may affect up to 1 in 10 patients)
Uncommon(may affect up to 1 in 100 patients)
Other side effects observed in transdermal patches and that may occur with hard capsules:
Common(may affect up to 1 in 10 patients)
Uncommon(may affect up to 1 in 100 patients)
Not known(frequency cannot be estimated from the available data)
If you experience any of these side effects, contact your doctor, as you may need medical attention.
Reporting of side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use Rivastigmine Sandoz after the expiration date stated on the blister, bottle, and carton after "EXP" or "CAD". The expiration date is the last day of the month indicated.
Medications should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Do not store above 30°C.
Rivastigmine Sandoz Composition
Each Rivastigmine Sandoz 1.5 mg capsule contains 1.5 mg of rivastigmine.
Each Rivastigmine Sandoz 3 mg capsule contains 3 mg of rivastigmine.
Each Rivastigmine Sandoz 4.5 mg capsule contains 4.5 mg of rivastigmine.
Each Rivastigmine Sandoz 6 mg capsule contains 6 mg of rivastigmine.
Product Appearance and Package Contents
It is packaged in blisters and is available in three different presentations (28, 56, or 112 capsules).
Marketing Authorization Holder
Sandoz GmbH
Biochemiestraße 10
A-6250 Kundl
Austria
Manufacturer
Novartis Farmacéutica, S.A.
Gran Via de les Corts Catalanes, 764
08013 Barcelona
Spain
Novartis Pharma GmbH
Roonstrasse 25
90429 Nuremberg
Germany
Salutas Pharma GmbH
Otto-Von-Guericke-Allee 1, Barleben,
Saxony-Anhalt, 39179,
Germany
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Belgium/Belgique/Belgien Sandoz N.V. Telecom Gardens, Medialaan 40 B-1800 Vilvoorde Tel: + 32 (0)2 722 97 97 | Luxembourg/Luxemburg Sandoz N.V. Telecom Gardens, Medialaan 40 B 1800 Vilvoorde Tel: + 32 (0)2 722 97 97 |
regaffairs.bg@sandoz.com | Hungary Sandoz Hungária Kft. Bartók Béla út 43-47 H-1114 Budapest Tel.: + 36 1 430 2890 E-mail: info.hungary@sandoz.com |
Czech Republic Sandoz s.r.o. Na Pankráci 1724/129 CZ-14000 Praha 4 - Nusle E-mail: office.cz@sandoz.com Tel: +420 225 775 111 | Malta Sandoz Pharmaceuticals d.d. Tel: +35699644126 |
Denmark Sandoz A/S Edvard Thomsens Vej 14 DK-2300 København S Denmark Tlf: +45 6395 1000 info.danmark@sandoz.com | Netherlands Sandoz BV Hospitaaldreef 29, NL-1315 RC Almere Tel: +31 36 5241600 E-mail: info.sandoz-nl@sandoz.com |
Germany Hexal AG Industriestraße 25 D-83607 Holzkirchen Tel: + 49 8024 908 0 E-mail: service@hexal.com | Norway Sandoz A/S Edvard Thomsens Vej 14 DK-2300 København S Denmark Tlf: +45 6395 1000 info.norge@sandoz.com |
Estonia Sandoz d.d. Eesti filiaal Pärnu mnt 105 EE-11312 Tallinn Tel: +372 6652400 | Austria Sandoz GmbH Biochemiestrasse 10 A-6250 Kundl Tel: + 43 (0)53382000 |
Greece SANDOZ HELLAS ΜΟΝΟΠΡΟΣΩΠΗ Α.Ε. Tel: +30 216 600 5000 | Poland Sandoz Polska Sp.z o.o. ul. Domaniewska 50 C PL-02-672 Warszawa Tel: + 48 22 549 15 00 |
Spain Sandoz Farmacéutica, S.A Centro Empresarial Parque Norte Edificio Roble C/ Serrano Galvache Nº 56, 28033 Madrid Tel: +34 900 456 856 registros.spain@sandoz.com | Portugal Sandoz Farmacêutica, Lda. Quinta da Fonte, Rua dos Malhões nº5, Edifício Q56 D. Pedro I, Piso 0 2770-071 Paço de Arcos Portugal Tel: +351 211 964 000 |
France Sandoz SAS 49, avenue Georges Pompidou F-92593 Levallois-Perret Cedex Tél: + 33 1 4964 4800 | Romania Sandoz S.R.L. Str Livezeni nr. 7A, Târgu Mures, 540472 Romania Tel: +40 21 310 44 30 |
Ireland Rowex Ltd. Newtown IE-Bantry Co. Cork P75 V009 Tel: +353 27 50077 | Slovenia Lek Pharmaceuticals d.d. Verovskova 57 SI-1526 Ljubljana Tel: + 386 1 5802111 E-mail: info.lek@sandoz.com |
Iceland Sandoz A/S Edvard Thomsens Vej 14 DK-2300 Kaupmannahöfn S Denmark Tlf: +45 6395 1000 info.danmark@sandoz.com | Slovak Republic Sandoz d.d. - organizačná zložka Žižkova 22B SK-811 02 Bratislava Tel: +421 2 48 200 600 |
Italy Sandoz S.p.a Largo Umberto Boccioni 1 I-21040 Origgio (VA) Tel: + 39 02 96541 | Finland Sandoz A/S Edvard Thomsens Vej 14 DK-2300 Kööpenhamina S/Köpenhamn S Denmark/Finland Puh: +358 010 6133 400 info.suomi@sandoz.com |
Cyprus Sandoz Pharmaceuticals d.d. Tel: +357 22 69 0690 | Sweden Sandoz A/S Edvard Thomsens Vej 14 DK-2300 Köpenhamn S Denmark Tel: +45 6395 1000 info.sverige@sandoz.com |
Latvia Sandoz d.d. Latvia filiale K.Valdemara Str. 33 – 29 LV-1010 Riga Tel: + 371 67892006 | United Kingdom (Northern Ireland) Sandoz Ltd Frimley Business Park Frimley Camberley Surrey GU16 7SR Tel: +44 1276 69 8020 E-mail: uk.drugsafety@sandoz.com |
Lithuania Sandoz Pharmaceuticals d.d., Branch Office Lithuania Seimyniskiu Str. 3A LT-09312 Vilnius Tel: + 370 5 2636037 | Croatia Sandoz d.o.o. Maksimirska 120 10 000 Zagreb Tel: +38512353111 E-mail: upit.croatia@sandoz.com |
This leaflet was last revised in
Detailed information on this medication is available on the European Medicines Agency website http://www.ema.europa.eu
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for RIVASTIGMINE SANDOZ 1.5 mg HARD CAPSULES – subject to medical assessment and local rules.